Tonix Pharmaceuticals CEO Dr. Seth Lederman recently announced on Proactive with Steve Darling that their COVID-19 vaccine, TNX-1800, has been selected for testing in Project Next Gen. This initiative is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.
TNX-1800 is a unique vaccine platform that uses a live virus method to stimulate the immune system. This approach provides longer-lasting immunity compared to mRNA vaccines and potentially blocks transmission of the virus. The selection of TNX-1800 for this program highlights Tonix Pharmaceuticals’ almost ten years of dedication to vaccine development. Furthermore, this technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis.
The choice of TNX-1800 represents the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. The platform’s adaptability makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.
For more information about Tonix Pharmaceuticals’ TNX-1800 vaccine and Project Next Gen, please contact Proactive Studio at +1 347-449-0879 or email them at na-editorial@proactiveinvestors.com
